Skip to main content
. Author manuscript; available in PMC: 2012 Jun 11.
Published in final edited form as: Eur J Pharmacol. 2011 Jan 1;660(1):80–87. doi: 10.1016/j.ejphar.2010.10.101

Figure 4.

Figure 4

Effect of JRH treatment on hypothalamic c-Fos-like immunoreactivity in wild type mice 2h after 3.0 nmol compound administration (n=3–4 animals per group). Statistical significance is observed for the JRH compounds in the PVN, but only for JRH887-9 in the DMH (***p<0.0001). The JRH322-18 compound is an MC3 antagonist as well as a MC4 agonist.